Biological agents in head and neck cancer

被引：2

作者：

Bossi, Paolo ^{[1
]}

Locati, Laura D. ^{[1
]}

Licitra, Lisa ^{[1
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Head & Neck Canc Med Oncol, I-20133 Milan, Italy

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2007年 / 7卷 / 11期

关键词：

biological agents; clinical trials; head and neck cancer; molecular basis;

D O I：

10.1586/14737140.7.11.1643

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Survival of head and neck cancer (HNC) patients has not dramatically improved over the last 30 years, despite the advances in surgical techniques, chemotherapeutic agents and radiotherapy treatment planning and definition. Different studies in molecular biology of HNC have been carried out, providing useful results for clinical application. HNC usually includes malignant tumors arising from mucosa of the upper aerodigestive tract, from nasopharynx to larynx/trachea, while salivary gland and thyroid cancers are less frequently listed in this classification. In this review, we chose to provide a comprehensive review of the role of biological agents in head and neck subsites. Molecular characteristics and treatment-relevant signaling pathways will be briefly discussed along with the results of the more recent clinical studies that include biological agents.

引用

页码：1643 / 1650

页数：8

共 94 条

[1]

ABIDOYE OO, 2006, 42 ASCO ANN M ATL GA

[2]

Agaoglu FY, 2004, IN VIVO, V18, P555

[3]

Agulnik M, 2006, ANN ONCOL, V17, P179

[4]

AHMED SM, 2007, 43 ASCO ANN M CHIC I

[5] Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands:: Report of two successfully treated cases [J].

Alcedo, JC ;

Fábrega, JM ;

Arosemena, JR ;

Urrutia, A .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2004, 26 (09) :829-831

[6]

Ang KK, 2002, CANCER RES, V62, P7350

[7]

ARGIRIS A, 2006, 42 ASCO ANN M ATL GA

[8] Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck [J].

Baselga, J ;

Trigo, JM ;

Bourhis, J ;

Tortochaux, J ;

Cortés-Funes, H ;

Hitt, R ;

Gascón, P ;

Arnellal, N ;

Harstrick, A ;

Eckardt, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5568-5577

[9]

BELON J, 2005, 41 ASCO ANN M ORL FL

[10] Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial [J].

Bentzen, SM ;

Atasoy, BM ;

Daley, FM ;

Dische, S ;

Richman, PI ;

Saunders, MI ;

Trott, KR ;

Wilson, GD .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5560-5567

← 1 2 3 4 5 6 7 8 9 10 →